Chronic rhinosinusitis with nasal polyps (CRSwNP) is typically characterized by Type 2 inflammation. Several biomarkers of eosinophilic inflammation, including Galectin-10, also known as Charcot-Leyden crystal protein (CLCP), have been identified to establish eosinophilic infiltration of polyps, a reliable predictor of recurrence.
Objective: We aimed to evaluate the Galectin-10 expression in nasal polyps of patients with CRSwNP and to assess the correlation of Charcot-Leyden crystals expression to the severity of CRSwNP according to Clinical-Cytological Grading (CCG).
Methods
A double-label immunofluorescence was performed to evaluate the expression of Gal-10, CD15, Tryptase, and CD63 and their eventual co-localization on histological samples of 18 patients with CRSwNP. Double-positive Gal-10+CD15+ and Galectin-10+Tryptase+ inflammatory cells were counted by confocal microscopy.
Results
Galectin-10 was detectable in all examined tissues from CRSwNP patients, and its expression increased as low, medium and high CCG tissues were examined, respectively. Galectin-10 was extensively present in inflammatory cells, while limited Galectin-10 deposits were detected around mucosal epithelial cells.
Conclusion
We showed the strong correlation between CCG and Galectin-10 expression, mainly colocalized with infiltrating eosinophils and mast-cells, in patients affected by CRSwNP.
BachertC.BhattacharyyaN.DesrosiersM.KhanA. H. Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps. J. Asthma Allergy. 2021; 14: 127–134.
2.
RyuG.KimD. W. Th2 inflammatory responses in the development of nasal polyps and chronic rhinosinusitis. Current Opinion in Allergy and Clinical Immunology vol. 201–8 (2020).
3.
StevensW. W.et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. J. Allergy Clin. Immunol. Pract. 7, 2812–2820.e3 (2019).
4.
TakabayashiT.et al. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis. Am. J. Rhinol. Allergy19458924211009428 (2021) doi:10.1177/19458924211009429.
5.
GanW.et al.The influence of nasal microbiome diversity and inflammatory patterns on the prognosis of nasal polyps. Sci. Rep.11, 6364 (2021).
6.
LiY.WangW.YingS.LanF.ZhangL. A Potential Role of Group 2 Innate Lymphoid Cells in Eosinophilic Chronic Rhinosinusitis With Nasal Polyps. Allergy. Asthma Immunol. Res.13, 363–374 (2021).
7.
PerssonE. K.et al.Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science364, (2019).
8.
ZhangM.YanB.WangY.WangC.ZhangL. Charcot-Leyden Crystal Protein in Nasal Secretions of Patients with Nonallergic Rhinitis with Eosinophilia Syndrome. Int. Arch. Allergy Immunol.1–9 (2020) doi:10.1159/000509252.
9.
ChuaJ. C.DouglassJ. A.GillmanA.O’HehirR. E.MeeusenE. N. Galectin-10, a potential biomarker of eosinophilic airway inflammation. PLoS One7, (2012).
10.
GelardiM.et al.Nasal-sinus polyposis: Clinical-cytological grading and prognostic index of relapse. J. Biol. Regul. Homeost. Agents23, 181–188 (2009).
11.
GelardiM.et al.Non-surgical management of chronic rhinosinusitis with nasal polyps based on clinical-cytological grading: a precision medicine-based approach. Acta Otorhinolaryngol. Ital.37, 38–45 (2017).
HefflerE.et al.Nasal cytology: Methodology with application to clinical practice and research. Clinical and Experimental Allergy vol. 481092–1106 (2018).
GelardiM.LandiM.CiprandiG. Nasal cytology: a Precision Medicine tool in clinical practice. Clinical and Experimental Allergy vol. 4896–97 (2018).
16.
GalloS.et al.Prognostic value of the sinonasal outcome test 22 (SNOT-22) in chronic rhinosinusitis. Acta Otorhinolaryngol. Ital.40, 113–121 (2020).
17.
StalloneG.et al.Semaphorin 3F expression is reduced in pregnancy complicated by preeclampsia. An observational clinical study. PLoS One12, (2017).
18.
NettiG. S.et al.LPS removal reduces CD80-mediated albuminuria in critically ill patients with gram-negative sepsis. Am. J. Physiol. - Ren. Physiol.316, F723–F731 (2019).
19.
NettiG. S.et al.PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. Aging (Albany. NY).12, 7585–7602 (2020).
20.
DwyerD. F.et al.Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation. Sci. Immunol.6, (2021).
21.
DelemarreT.et al.A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps. J. Allergy Clin. Immunol.147, 179–188.e2 (2021).
22.
LouH.et al.Cellular phenotyping of chronic rhinosinusitis with nasal polyps. Rhinol. J.54, 150–159 (2016).
23.
LiuC.et al.Predictive Significance of Charcot–Leyden Crystals for Eosinophilic Chronic Rhinosinusitis With Nasal Polyps. Am. J. Rhinol. Allergy33, 671–680 (2019).
24.
MulayS. R. & Anders, H.-J. Crystallopathies. N. Engl. J.Med.374, 2465–2476 (2016).
25.
WuD.YanB.WangY.ZhangL.WangC. Predictive significance of charcot-leyden crystal protein in nasal secretions in recurrent chronic rhinosinusitis with nasal polyps. Int. Arch. Allergy Immunol. (2020) doi:10.1159/000510120.
26.
WuD.YanB.WangY.ZhangL.WangC. Predictive Significance of Charcot-Leyden Crystal Protein in Nasal Secretions in Recurrent Chronic Rhinosinusitis with Nasal Polyps. Int. Arch. Allergy Immunol.182, 65–75 (2021).
27.
SuJ.et al.Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology28, 159–168 (2018).
28.
GelardiM.et al.Clinical-cytological-grading and phenotyping in patients with chronic rhinosinusitis with nasal polyps: The relevance in clinical practice. Monaldi Arch. Chest Dis.90, 348–352 (2020).
29.
PetersA. T.et al.Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps. J. Allergy Clin. Immunol. Pract. (2021) doi:10.1016/j.jaip.2021.01.031.
30.
BachertC.et al.Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet394, 1638–1650 (2019).
31.
FokkensW. J.et al.European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology58, 1–464 (2020).
32.
YimM. T.OrlandiR. R.OakleyG. M.AltJ. A. The Sinonasal Outcome Test (SNOT-22) Is a Poor Diagnostic Tool for Chronic Rhinosinusitis. Ann. Otol. Rhinol. Laryngol. (2021) doi:10.1177/0003489421998213.
